17β-Estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice

GLIA

Volumn 57, Issue 8, 2009, Pages 807-814

  Acs, Peter ^a   Kipp, Markus ^b   Norkute, Akvile ^b   Johann, Sonja ^b   Clarner, Tim ^b   Braun, Alena ^b   Berente, Zoltan ^a   Komoly, Samuel ^a   Beyer, Cordian ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Estrogen; Hormones; Multiple sclerosis; Neuroprotection

Indexed keywords

CELL MARKER; CUPRIZONE; ESTRADIOL; MESSENGER RNA; MYELIN BASIC PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGESTERONE; PROTEOLIPID PROTEIN; SOMATOMEDIN C; ESTROGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CELL FUNCTION; CELL INTERACTION; CELL INVASION; CELLULAR DISTRIBUTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATING DISEASE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HYDROCEPHALUS; IMAGE ANALYSIS; MALE; MICROGLIA; MONOTHERAPY; MOUSE; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEUROPHYSIOLOGICAL RECRUITMENT; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMYELINIZATION; STAINING; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOSKELETON; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; CORPUS CALLOSUM; CUPRIZONE; CYTOSKELETON; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGENS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MYELIN PROTEINS; PROGESTERONE; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 67649948190     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20806     Document Type: Article

References (49)

1. Aberg ND, Johansson UE, Aberg MA, Hellstrom NA, Lind J, Bull C, Isgaard J, Anderson MF, Oscarsson J, Eriksson PS. 2007. Peripheral infusion of insulin-like growth factor-I increases the number of newborn oligodendrocytes in the cerebral cortex of adult hypophysectomized rats. Endocrinology 148:3765-3772.
2. Boggs JM. 2006. Myelin basic protein: A multifunctional protein. Cell Mol Life Sci 63:1945-1961.
3. Bruck W, Lucchinetti C, Lassmann H. 2002. The pathology of primary progressive multiple sclerosis. Mult Scler 8:93-97.
4. Cui QL, Almazan G. 2007. IGF-I-induced oligodendrocyte progenitor proliferation requires PI3K/Akt, MEK/ERK, and Src-like tyrosine kinases. J Neurochem 100:1480-1493.
5. Darlington CL. 2005. Astrocytes as targets for neuroprotective drugs. Curr Opin Investig Drugs 6:700-703.
6. Dwosh E, Guimond C, Duquette P, Sadovnick AD. 2003. The interaction of MS, pregnancy: A critical review. Int MS J 10:38-42.
7. Etgen AM, Gonzalez-Flores O, Todd BJ. 2006. The role of insulin-like growth factor-I and growth factor-associated signal transduction pathways in estradiol and progesterone facilitation of female reproductive behaviors. Front Neuroendocrinol 27:363-375.
8. Garay L, Deniselle MC, Lima A, Roig P, De Nicola AF. 2007. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 107:228-237.
9. Garcia-Segura LM, Azcoitia I, DonCarlos LL. 2001. Neuroprotection by estradiol. Prog Neurobiol 63:29-60.
10. Garcia-Segura LM, Diz-Chaves Y, Perez-Martin M, Darnaudery M. 2007. Estradiol, insulin-like growth factor-I and brain aging. Psychoneuroendocrinology 32 Suppl 1:S57-S61.
11. Gibson CL, Gray LJ, Bath PM, Murphy SP. 2008. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131(Pt 2):318-328.
12. Gold R, Linington C, Lassmann H. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8):1953-1971.
13. Hoffman GE, Le WW, Murphy AZ, Koski CL. 2001. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. Exp Neurol 171:272-284.
14. Irvine KA, Blakemore WF. 2008. Remyelination protects axons from demyelination-associated axon degeneration. Brain 131(Pt 6):1464-1477.
15. Jansson L, Olsson T, Holmdahl R. 1994. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol 53:203-207.
16. Johann S, Kampmann E, Denecke B, Arnold S, Kipp M, Mey J, Beyer C. 2008. Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes after LPS-induced inflammation. J Mol Neurosci 34:177-185.
17. Kajta M, Trotter A, Lason W, Beyer C. 2006. Impact of 17beta-estradiol on cytokine-mediated apoptotic effects in primary hippocampal and neocortical cell cultures. Brain Res 1116:64-74.
18. Kesterson JW, Carlton WW. 1970. Aqueductal stenosis as the cause of hydrocepahlus in mice fed the substituted hydrazine, cuprizone. Exp Mol Pathol 13:281-294.
19. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. 1999. Estriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis. Neurology 52:1230-1238.
20. Kipp M, Karakaya S, Johann S, Kampmann E, Mey J, Beyer C. 2007. Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in mid-brain astrocytes. J Neuroendocrinol 19:819-822.
21. Kipp M, Karakaya S, Pawlak J, Araujo-Wright G, Arnold S, Beyer C. 2006. Estrogen and the development and protection of nigrostriatal dopaminergic neurons: Concerted action of a multitude of signals, protective molecules, and growth factors. Front Neuroendocrinol 27:376-390.
22. Kipp M, Norkute A, Johann S, Lorenz L, Braun A, Hieble A, Gingele S, Pott F, Richter J, Beyer C. 2008. Brain-region-specific astroglial responses in vitro after LPS exposure. J Mol Neurosci 35:235-243.
23. Kleinschnitz C, Meuth SG, Stuve O, Kieseier B, Wiendl H. 2007. Multiple sclerosis therapy: An update on recently finished trials. J Neurol 254:1473-1490.
24. Komoly S, Hudson LD, Webster HD, Bondy CA. 1992. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 89:1894-1898.
25. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ. 2001. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 35:204-212.
26. Lassmann H, Bruck W, Lucchinetti CF. 2007. The immunopathology of multiple sclerosis: An overview. Brain Pathol 17:210-218.
27. Lucchinetti C, Bruck W. 2004. The pathology of primary progressive multiple sclerosis. Mult Scler 10 Suppl 1:S23-S30.
28. Mason JL, Langaman C, Morell P, Suzuki K, Matsushima GK. 2001. Episodic demyelination and subsequent remyelination within the murine central nervous system: Changes in axonal calibre. Neuropathol Appl Neurobiol 27:50-58.
29. Matsushima GK, Morell P. 2001. The neurotoxicant cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.
30. McEwen BS, Alves SE. 1999. Estrogen actions in the central nervous system. Endocr Rev 20:279-307.
31. Mendez P, Wandosell F, Garcia-Segura LM. 2006. Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: Cellular and molecular mechanisms. Front Neuroendocrinol 27:391-403.
32. Moscarello MA, Mastronardi FG, Wood DD. 2007. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 32:251-256.
33. Offner H, Polanczyk M. 2006. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1089:343-372.
34. Palaszynski KM, Liu H, Loo KK, Voskuhl RR. 2004. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. J Neuroimmunol 149:84-89.
35. Pawlak J, Brito V, Kuppers E, Beyer C. 2005a. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 138:1-7.
36. Pawlak J, Karolczak M, Krust A, Chambon P, Beyer C. 2005b. Estrogen receptor-alpha is associated with the plasma membrane of astrocytes and coupled to the MAP/Src-kinase pathway. Glia 50:270-275.
37. Pittock SJ, Lucchinetti CF. 2007. The pathology of MS: New insights and potential clinical applications. Neurologist 13:45-56.
38. Quesada A, Lee BY, Micevych PE. 2008. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 68:632-644.
39. Remington LT, Babcock AA, Zehntner SP, Owens T. 2007. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 170:1713-1724.
40. Salmaso N, Woodside B. 2008. Fluctuations in astrocytic basic fibroblast growth factor in the cingulate cortex of cycling, ovariectomized and postpartum animals. Neuroscience 154:932-939.
41. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR. 2002. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52:421-428.
42. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, Trebst C, Stangel M. 2008. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172:1053-1061.
43. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. 2003. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 171:6267-6274.
44. Stadelmann C, Albert M, Wegner C, Bruck W. 2008. Cortical pathology in multiple sclerosis. Curr Opin Neurol 21:229-234.
45. Turrin NP, Rivest S. 2006. Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J Neurosci 26:143-151.
46. Voskuhl RR. 2003. Hormone-based therapies in MS. Int MS J 10:60-66.
47. Wegmann TG, Lin H, Guilbert L, Mosmann TR. 1993. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a TH2 phenomenon? Immunol Today 14:353-356.
48. Worthington J, Jones R, Crawford M, Forti A. 1994. Pregnancy and multiple sclerosis-a 3-year prospective study. J Neurol 241:228-233.
49. Zeger M, Popken G, Zhang J, Xuan S, Lu QR, Schwab MH, Nave KA, Rowitch D, D'Ercole AJ, Ye P. 2007. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55:400-411.